Introduction {#s1}
============

Accumulation of amyloid-beta (Aβ) in plaques, along with tau tangles, is one of the two pathological hallmarks of Alzheimer's disease (AD). Change in Aβ levels in the brain is one of the earliest known pathological events in AD and is detectable years before the development of Aβ plaques and decades before the clinical onset of AD ([@bib6]; [@bib23]). Because of its importance in AD progression, Aβ has been mostly characterized as a functionless, pathological, intrinsically neurotoxic peptide ([@bib39]). However, Aβ is an ancient neuropeptide conserved across vertebrates through at least 400 million years of evolution ([@bib39]). Aβ's cleavage from amyloid precursor protein (APP) is tightly regulated by multiple enzymatic reactions ([@bib44]), and its release from neurons is carefully controlled ([@bib25]). Aβ interacts with numerous surface receptors and can activate intrinsic cellular signalling cascades to alter neuronal and synaptic function ([@bib24]). More recently, Aβ has been suggested to act as an [antimicrobial peptide](https://www.sciencedirect.com/topics/neuroscience/antimicrobial-peptides) ([@bib55]), and the deposition of Aβ may be induced as an innate immune [defence mechanism](https://www.sciencedirect.com/topics/neuroscience/defence-mechanisms) against microbial pathogens ([@bib29]). However, the various biological effects of Aβ in health or disease remain obscure.

One of the earliest symptoms of AD is the disruption of sleep, and AD patients have sleep-wake abnormalities, including insomnia at night and increased napping during the day ([@bib1]; [@bib36]; [@bib40]; [@bib46]). Multiple transgenic AD mouse models that overproduce Aβ also show disrupted sleep phenotypes ([@bib52]; [@bib57]; [@bib65]), often in the absence of neuronal loss and preceding impairments of learning and memory ([@bib20]). In non-pathological conditions, Aβ levels in the cerebrospinal fluid (CSF) are modulated by the sleep-wake cycle ([@bib26]; [@bib69]). Aβ generation and release are controlled by electrical and synaptic activity ([@bib9]; [@bib25]), leading to increased extracellular Aβ levels during wakefulness and decreased levels during sleep ([@bib26]; [@bib69]). These observations have led to the proposal that sleep and Aβ dynamics create a vicious feed-forward cycle, wherein increases in wakefulness result in increased extracellular Aβ and aggregation, which then dysregulates sleep, further exacerbating pathogenic Aβ production ([@bib52]). How increased Aβ burden leads to disruptions in sleep remains unknown, although AD-related cell death of critical sleep/wake regulatory neurons has been suggested as a possible mechanism ([@bib14]; [@bib35]; [@bib38]).

Given the relationship between Aβ and sleep, we hypothesized that Aβ may directly modulate sleep-regulatory pathways independently of neuronal cell death. To test this, we took advantage of the ability to directly deliver small molecules and Aβ peptides to the brain of larval zebrafish, which have conserved APP processing machinery and Aβ peptides ([@bib41]) and share genetic, pharmacological, and neuronal sleep-regulatory mechanisms with mammals ([@bib5]). We found that Aβ size-dependently and reversibly modulates behavior through two distinct genetic, pharmacologically tractable pathways that regulate sleep in opposing directions.

Results {#s2}
=======

Aβ dose-dependently modifies zebrafish sleep and wake behavior {#s2-1}
--------------------------------------------------------------

Isolating the specific biological effects of Aβ has been experimentally difficult. One challenge is that Aβ is processed from a series of complex cleavage steps of a longer transmembrane protein, APP, which also produces other protein products with a variety of functions ([@bib44]). This restricts the utility of genetic manipulations to tease out Aβ-specific roles from the other APP components. Another challenge is that Aβ forms, in vitro and in vivo, a variety of oligomeric species (e.g. dimers, longer oligomers, or large fibrils) with diverse structures, binding affinities, and signalling properties ([@bib7]; [@bib24]). Teasing out the biological signalling capabilities of these diverse oligomeric species requires selective manipulation of Aβ oligomeric states, which is difficult in vitro and is currently nearly impossible endogenously in vivo.

To overcome some of these barriers, we developed an injection assay in which the amount and type of the Aβ oligomers can be controlled and then tested the acute signaling effects of Aβ on sleep and wake behavior. Our minimally invasive intra-cardiac injection assay in 5 days post fertilization (5 dpf) larval zebrafish avoids direct damage to brain tissue ([Figure 1A and B](#fig1){ref-type="fig"}). This technique rapidly (\<1 hr, peaking within 2--3 hr) and reversibly delivers Aβ to the larval brain, as assessed by injection of fluorescently tagged Aβ42 and subsequent confocal brain imaging ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). To generate different Aβ oligomeric species, we modified previously established in vitro monomeric Aβ incubation protocols (see Extended Methods) that enrich for Aβ with different oligomeric sizes and opposing effects on rat neuronal excitability ([@bib30]; [@bib45]; [@bib68]). By incubating Aβ42 overnight at increasing temperatures, we generated Aβ oligomeric pools with significantly different lengths, as measured by transmission electron microscopy (TEM) ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Aβ42 incubated overnight at 4°C consisted of fewer and shorter oligomers (Aβ^short^, mean 45 ± 11 nm, median = 39 nm) than when incubated at 25°C (Aβ^long^, mean 75 ± 10 nm, median = 61 nm) or at 37°C (Aβ^v-long^, mean 121 ± 10 nm, median = 88 nm) ([Figure 1C](#fig1){ref-type="fig"}).

![Aβ oligomers bi-directionally affect sleep and wake in zebrafish larvae.\
(**A**) Experimental schematic. Aβ was injected into the heart of 5 dpf larvae in the morning (ZT2 = zeitgeber time 2, that is 2hr after lights on). Behavior was then monitored in a square-welled 96-well plate for 24--48 hr on a 14 hr:10 hr light:dark cycle. (**B**) Heart-injected HiLyteTM Fluor 647-labeled Aβ42 (fAβ) penetrated the whole larval brain as visualized by confocal microscopy (optical sections, dorsal view) taken 2 hr after injection. Anterior is to the top. (**C**) Aβ prepared under increasing temperatures adopted longer oligomeric lengths, as measured by transmission electron microscopy. Each dot is a single oligomer (N = number measured), and the bars show the median. Data was taken from five randomly selected micrographs from two independent experiments. \*\*p≤0.01, \*\*\*\*p≤1×10-7 Kruskal-Wallis, Tukey-Kramer post-hoc test. (**D, E**) Exemplar 24 hr traces post-injection comparing the effect of Aβ^short^ (blue) on average waking activity (**D**) and sleep (**E**) versus Aβ^rev^ controls (grey). Ribbons represent ±the standard error of the mean (SEM). Light and dark bars indicate the lights ON and lights OFF periods, respectively. N = the number of larvae in each condition. (**D', E'**) The effect of Aβ^short^ relative to Aβ^rev^ on waking (**D'**) and sleep (**E'**) during the first day is shown, pooled from n = 5 independent experiments. Each dot represents a single larva normalized to the mean of the Aβ^rev^ control, and error bars indicate ± SEM. The mean difference effect size and 95% confidence interval is plotted to the right. \*p\<0.05, ^T^p \<0.1, one-way ANOVA. (**F, G**) Exemplar 24 hr traces post-injection comparing the effect of Aβ^long^ (green) on average waking activity (**F**) and sleep (**G**) versus Aβ^rev^ controls (grey). (**F', G'**) The effect of Aβ^long^ relative to Aβ^rev^ on waking (**F'**) and sleep (**G'**) during the first day is shown, pooled from n = 4 independent experiments. \*p\<0.05, \*\*p\<0.01, one-way ANOVA. (**H, I**) Exemplar 24 hr traces post-injection comparing the effect of Aβ^v_long^ (magenta) on average waking activity (**H**) and sleep (**I**) versus Aβ^rev^ peptide controls (grey). (**H', I'**) The effect of Aβ^v_long^ relative to Aβ^rev^ on waking (**H'**) and sleep (**I'**) during the first day is shown, pooled from n = 3 independent experiments. (**J**) The effect of different Aβ preparations on the number of sleep bouts relative to Aβ^rev^ controls. The difference effect size and 95% confidence interval is plotted below. The asterisks indicate statistically significant different effects among the preps (\*\*\*p\<0.001, one-way ANOVA). See also [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[3](#fig1s3){ref-type="fig"}.](elife-53995-fig1){#fig1}

We then assessed how each Aβ preparation affected sleep and wake behavior in zebrafish relative to an Aβ42--1 'reverse' peptide control (Aβ^rev^) using automated video-monitoring ([@bib47]; [@bib50]). In initial experiments, we determined the appropriate Aβ injection dose by injecting 1 nL of a 1--1000 nM dose series for both Aβ^short^ and Aβ^long^ and assessing subsequent waking activity and sleep, which is defined in zebrafish larvae as a period of inactivity lasting longer than one minute, which are associated with an increased arousal threshold and other features of behavioral sleep ([@bib47]). Unexpectedly, these oligomeric species had opposing behavioral effects ([Figure 1---figure supplement 1D--G](#fig1s1){ref-type="fig"}). Aβ^short^ increased waking activity and decreased sleep relative to Aβ^rev^ peptide, while Aβ^long^ decreased waking and increased sleep (prep waking effect, p\<0.001; prep sleep effect p\<0.05, two-way ANOVA). These effects were generally consistent across doses, although some dose-responses elicited stronger differential effects than others ([Figure 1---figure supplement 1D,E](#fig1s1){ref-type="fig"}), with the maximal difference between the Aβ^short^ and Aβ^long^ preparations at 10 nM (p[\<]{.ul}0.01 doseXprep interaction, two-way ANOVA). We estimate this dose yields a final concentration that falls within the lower range of physiological concentrations reported for Aβ42 in human CSF of 100 pM-5nM ([@bib6]). For example, assuming that all injected Aβ goes into the brain, the highest possible concentration would be 1500 pg/ml or 300 pM (45 ng/ml x 1 nl in 30.4 nl brain = 1.5 ng/ml = 1500 pg/ml). At the lower end, assuming equal distribution of Aβ over the whole body yields a final concentration estimate of 150 pg/ml or 30 pM (45 ng/ml x1 nl in 300 nl of body = 150 pg/ml). We therefore continued with 10 nM injections for all subsequent experiments, as it combines the maximal differentially observed behavioral effects between Aβ^short^ and Aβ^long^ with physiologically reasonable concentrations.

Aβ affects sleep and wake in opposing directions as a function of oligomer size and independently of neural death {#s2-2}
-----------------------------------------------------------------------------------------------------------------

To explore the effect of Aβ oligomeric size on sleep, we then systematically tested the behavior effects of each Aβ species relative to a Aβ^rev^ control for n = 3--5 independent experiments each. As in the dose response experiments, Aβ affected sleep and wake in opposing directions depending on its oligomeric state ([Figure 1D--I'](#fig1){ref-type="fig"}). In the day following injection, Aβ^short^ significantly increased waking activity by +12.8% and reduced total sleep relative to Aβ^rev^ by 15.5% ([Figure 1D--E'](#fig1){ref-type="fig"}). The magnitude of the sleep effect is likely partially masked by a flooring effect due to generally reduced sleep during the day; we therefore favor reporting effect sizes and confidence intervals as recommended ([@bib2]; [@bib18]). Indeed, if we were to combine all the additional control Aβ^short^ experiments subsequently reported in this manuscript (n = 160 Aβ^rev^n = 164 Aβ^short^, see Figure 3G and H), the effect size remains robust at −15.9% and the result is statistically significant (p\<0.05, one-way ANOVA). These effects were reversible, as there were no significant differences in sleep ([Figure 1E](#fig1){ref-type="fig"}, black bar) or waking activity ([Figure 1D](#fig1){ref-type="fig"}, black bar) between Aβ^short^ and reverse peptide in the night following injection, and the behavior of Aβ^short^-injected larvae returned to baseline levels in the subsequent day ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}).

In contrast, while injection of longer Aβ fibers (Aβ^v_long^) had no effect on behavior, ([Figure 1H--I'](#fig1){ref-type="fig"}), injection of the intermediate Aβ^long^ oligomers significantly increased sleep during the post-injection day by +47.2% and reduced waking activity by 11.3% ([Figure 1F--G'](#fig1){ref-type="fig"}). The increased sleep induced by Aβ^long^ was due to a significant increase in the average number of sleep bouts but not an increase in sleep bout length ([Figure 1J](#fig1){ref-type="fig"}), indicating higher sleep initiation is responsible for the change in sleep rather than an increased sleep consolidation. This increased sleep effect by Aβ^long^ was not observed in the night following injection ([Figure 1F and G](#fig1){ref-type="fig"}, black bar), and behavior returned to baseline by the following morning ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}).

This data is consistent with Aβ^short^ increasing wakefulness and Aβ^long^ decreasing wakefulness and increasing sleep. Additional control experiments ruled out experimental artefacts, as larvae undergoing no treatment, anesthesia only, mock injection, or PBS only injections had indistinguishable effects on sleep/wake ([Figure 1---figure supplement 1H--J](#fig1s1){ref-type="fig"}). Next, we recalculated the behavioral analysis only for the evening period before lights off, when vehicle-injected larvae were statistically indistinguishable from larvae that had been acclimated to the tracking rig for 24 hr ([Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}). Except for an even more severe flooring effect in the Aβ^short^ injection experiments, the results from evening-only analysis were indistinguishable from calculations across the whole day ([Figure 1---figure supplement 1K](#fig1s1){ref-type="fig"}). We therefore used full day analysis for all subsequent experiments.

We next considered if the dual-effects of Aβ on sleep and wake are due to either neuronal damage or generalized toxic effects, such as the induction of seizure, paralysis, or sickness behavior.

First, injection with either long or short forms of Aβ had no effect on apoptosis, as detected by staining for activation of Caspase-3 ([Figure 1---figure supplement 2A--C](#fig1s2){ref-type="fig"}). In addition, Aβ injected animals raised to adulthood showed no major differences in their general health or in their survival rates ([Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}). Moreover, injected animals recovered fully in the long term, returning to baseline sleep and activity levels within 24 hr ([Figure 1---figure supplement 3A,B](#fig1s3){ref-type="fig"}). Second, both Aβ^short^ and Aβ^long^ injected larvae responded normally to salient stimuli such as a light:dark pulse, demonstrating that these larvae were not paralyzed, in a coma, or undergoing sickness behavior ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). Finally, we considered if the changes in motility in Aβ-injected larvae were seizure-like behaviors. Wild type (WT) zebrafish larvae display 'burst-and-glide' movements characterized by single short forward or turn movement followed by a short pause ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"} and [Figure 1---video 1](#fig1video1){ref-type="video"}). In contrast, epileptogenic drugs like the GABA-receptor antagonist PTZ induce electrophysiological and behavioral seizures ([@bib4]), which are observed as dramatic rearrangements in zebrafish bout structure ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). The bout structure of Aβ^rev^, Aβ^short^, and Aβ^long^ injected fish was highly similar to WT behavior ([Figure 1---figure supplement 3D,E](#fig1s3){ref-type="fig"} and [Figure 1---video 1](#fig1video1){ref-type="video"}), and the high-frequency bouts (HFB) indicative of seizures ([@bib49]) were only found in PTZ exposed fish but not Aβ injected larvae ([Figure 1---figure supplement 3D,E](#fig1s3){ref-type="fig"}). Together these experiments indicate that exposure to Aβ modulates normal sleep/wake behavior without inducing toxic states.

We conclude that the changes in behavior after Aβ exposure are due to acute signalling events and therefore sought to identify the neuronal and molecular substrates through which Aβ signals to modulate sleep/wake behavior.

Aβ^short^ and Aβ^long^ induce opposing changes in neuronal activity and differentially engage sleep-promoting neurons {#s2-3}
---------------------------------------------------------------------------------------------------------------------

If Aβ oligomers alter behavior through acute signaling in the brain, the differential effects of Aβ^short^ and Aβ^long^ should be reflected at the level of neuronal activity. In situ hybridization (ISH) for expression of the immediate early gene, *c-fos*, identified several discrete areas of the larval brain that are upregulated after injection of Aβ^short^ relative to Aβ^rev^, including the posterior hypothalamus and the dorsal and ventral telencephalon ([Figure 2A](#fig2){ref-type="fig"}), areas that are also upregulated in mutants with extended wakefulness ([@bib3]). Comparing the Aβ^short^ induced *c-fos* patterns to WT brains collected at zeitgeber time 1 (ZT1, ZT0 = lights ON), when larvae are maximally awake, reveals at least nine populations of *c-fos-*positive neurons in both Aβ^short^ and waking brains ([Figure 2A,C](#fig2){ref-type="fig"}). In contrast, *c-fos* expression following Aβ^long^ injections was globally dampened relative to Aβ^rev^ ([Figure 2B](#fig2){ref-type="fig"}) in a manner consistent with the low expression of *c-fos* in WT brains collected at ZT19, when larvae are maximally asleep ([Figure 2C](#fig2){ref-type="fig"}).

![Aβ oligomers differentially alter neuronal activity in the larval zebrafish brain.\
(**A**) As detected by ISH, the immediate early gene *c-fos* is upregulated in many larval brain areas following Aβ^short^ injection, including the dorsal and ventral telencephalon (tel) and the posterior hypothalamus (black arrowheads), relative to Aβ^rev^ control injections. Other upregulated areas in the midbrain and hindbrain are indicated (white arrowheads). hyp- hypothalamus; hb- hindbrain. D = dorsal, p=Posterior, R = Right. n = blind counts of brains with the shown expression pattern/total brains. 24/43 stringently counts only brains with the major areas upregulated. (**B**) Compared to Aβ^rev^ injections, Aβ^long^ oligomers induce less *c-fos* expression. The Aβ^rev^ and Aβ^long^ treated brains were stained longer than in (**A**) to ensure detection of weaker *c-fos* expression. n = blind counts of number of brains with the shown expression/total brains. (**C**) *c-fos* is upregulated in many larval brain areas at 10 am (ZT1) awake fish, including the dorsal and ventral telencephalon and the posterior hypothalamus (black arrowheads), and other discrete regions of the mid and hindbrain (white arrowheads). *c-fos* expression is downregulated in later timepoints (ZT13) and is very low in ZT19 brains, when larvae are predominantly asleep. N = 10 fish/timepoint. (**D, D'**) Brain expression of the neuronal activity correlate pERK/tERK comparing Aβ^short^ (n = 6) to Aβ^rev^ (n = 5) injected larvae identified areas upregulated (green) and downregulated (magenta) by Aβ^short^. Data are shown as a thresholded maximum projection overlaid on the Z-Brain Atlas tERK reference (gray). White arrowheads indicate regions in the ventral telencephalon and posterior hypothalamus that are upregulated similar to *c-fos* in (**A**). Dorsal view in (**D**), lateral view in (**D'**). (**E, E'**) pERK/tERK expression after Aβ^long^ injections (n = 7) shows widespread downregulation of neuronal activity (magenta) compared to Aβ^rev^ controls (n = 7), consistent with *c-fos* data in (**B**). Dorsal view in (**E**), lateral view in (**E'**). (**F**) As detected by ISH, the number and intensity of hypothalamic *galanin*-positive neurons are downregulated following Aβ^short^ injection and upregulated following Aβ^long^ injection, relative to Aβ^rev^ control injections. Representative images from N = 22--24 per condition. (**G**) Normalized, blinded counts of hypothalamic *galanin*-positive cell numbers 4--6 hr after Aβ^short^ and Aβ^long^ injections, relative to Aβ^rev^. Error bars indicate ± SEM. The mean difference effect size and 95% confidence interval is plotted at the bottom. \*\*p\<0.01, one-way ANOVA. See also [Figure 2---source datas 1](#fig2sdata1){ref-type="supplementary-material"} and [2](#fig2sdata2){ref-type="supplementary-material"}.\
Figure 2---source data 1.MAP-Mapping of brain areas that are significantly up- and down-regulated in P-ERK levels in response to Aβ^short^.\
Figure 2---source data 2.MAP-Mapping of brain areas that are significantly up- and down-regulated in P-ERK levels in response to Aβ^long^.](elife-53995-fig2){#fig2}

Immediate early gene expression is an imperfect readout of changes in neuronal activity and brain state, as baseline *c-fos* is expressed in low amounts in zebrafish and has a relatively slow time course of 15--30 min for transcription of mRNA ([@bib4]). We therefore also quantified changes in the more rapid (\<5 min) neuronal activity marker, phosphorylated ERK (p-ERK), using the larval zebrafish MAP-Mapping technique ([@bib48]). This method identifies the relative quantitative changes in brain region-specific levels of p-ERK relative to total ERK between Aβ injections and reverse peptide control conditions. Consistent with *c-fos* induction, Aβ^short^ upregulated P-ERK in the ventral telencephalon and posterior hypothalamus ([Figure 2D and D'](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), while Aβ^long^ resulted in a widespread reduction in p-ERK levels throughout most of the brain ([Figure 2E and E'](#fig2){ref-type="fig"}, [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). These brain activity states are consistent with the induction of wakefulness by Aβ^short^ and sleep by Aβ^long^.

Finally, if the behavioral states induced by Aβ are bona fide sleep/wake states, we reasoned that known zebrafish sleep/wake regulatory neurons should be engaged. Galanin-expressing neurons of the preoptic area and hypothalamus are active and upregulate *galanin* transcription during zebrafish sleep ([@bib49]). Similarly, ISH for galanin 4--6 hr post-injection of Aβ oligomers revealed that wake-promoting Aβ^short^ slightly decreased (−6%, blinded counts), while sleep-promoting Aβ^long^ slightly increased (+12%, blinded counts), the number of *galanin*-positive cells in the hypothalamus compared to Aβ^rev^ injected larvae ([Figure 2F--G](#fig2){ref-type="fig"}). The differential effects on *galanin* neurons are consistent with that the induction of wakefulness by Aβ^short^ and sleep by Aβ^long^.

Aβ binding targets are required for behavioral responses to Aβ {#s2-4}
--------------------------------------------------------------

Many candidate Aβ binding partners have been implicated in mediating the signalling effects of Aβ on synapses, with some targets showing preferences for Aβ dimers, such as Adrenergic Receptor β2 (ADRB2) ([@bib67]), or low molecular weight (50--75 kDa) species, such as the Progesterone Membrane Receptor Component 1 (PGRMC1) ([@bib22]), while other targets preferentially bind to longer oligomers/protofibrils, such as the Prion Protein (PrP) ([@bib32]; [@bib42]). We therefore used Crispr/Cas9 to make genetic lesions in several zebrafish candidate Aβ receptors, choosing examples with reported affinities for various sized Aβ oligomers ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We isolated a *pgrmc1* allele with a 16 bp deletion that leads to a frameshift and early stop codon that truncates the protein before a conserved Cytochrome b5-like Heme/Steroid binding domain ([Figure 3---figure supplement 1A--D](#fig3s1){ref-type="fig"}). We also isolated an *adrb2a* allele with an 8 bp deletion that leads to a severely truncated protein lacking all transmembrane domains ([Figure 3---figure supplement 1E--G](#fig3s1){ref-type="fig"}). We also obtained a *prp1^-/-^;prp2^-/-^* double mutant ([@bib13]; [@bib33]) that lacks both zebrafish Prp proteins with conserved Aβ binding sites ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The third zebrafish *prion* gene product, Prp3, does not have the conserved Aβ binding domains present in Prp1 and Prp2 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Except for a mild increase in daytime sleep in *adrb2a*^-/-^ mutants ([Figure 3---figure supplement 2D\'--F'](#fig3s2){ref-type="fig"}), none of these mutants exhibited changes in baseline sleep and wake on a 14 hr:10 hr light:dark cycle as compared to wild type and heterozygous siblings ([Figure 3---figure supplement 2A--F'](#fig3s2){ref-type="fig"}; [Figure 4---figure supplement 2A--F'](#fig4s2){ref-type="fig"}). Under baseline conditions, we also detected no significant differences in day or night sleep and waking activity in *prp1^-/-^;prp2^-/-^* double mutants compared to *prp*^+/+^ siblings generated from either *prp1^+/-^; prp2^+/-^* or *prp1^+/-^;prp2^-/-^* in-crosses ([Figure 4---figure supplement 2A--F'](#fig4s2){ref-type="fig"}). The mild baseline phenotypes allowed us to test the effect of Aβ oligomers in these mutants without complex behavioral confounds.

We first tested the effects of Aβ^short^ injection on mutant behavior. Unlike the wild type controls, neither the *adrb2a^-/-^* nor the *pgrmc1^-/-^* mutants increased waking activity ([Figure 3A--C and E](#fig3){ref-type="fig"}) or suppressed sleep as observed in wild-type controls ([Figure 3A'--C' and G](#fig3){ref-type="fig"}). Injection of Aβ^short^ into *adrb2a*^-/-^ animals even significantly increased sleep (+83.7%) instead of reducing it as in wild-type larvae ([Figure 3B' and G](#fig3){ref-type="fig"}). In contrast, Aβ^short^ injected into mutants that lack both zebrafish Prp orthologs (*prp1^-/-^; prp2^-/-^*) elicited slightly stronger increases in waking activity and significantly large (−45%) reductions in sleep ([Figure 3D,D', F and H](#fig3){ref-type="fig"}). Thus, the wake-promoting activity of Aβ^short^ requires intact Adrb2a and Pgrmc1 but not functional Prp1 and Prp2.

![Wake induction by Aβ^short^ requires Adrb2a and Pgrmc1, but not the Prion Protein.\
(**A-D'**) Exemplar 24 hr traces comparing the effects of Aβ^short^ oligomers on average waking activity (A-D) and sleep (**A'-D'**) versus Aβ^rev^ injected into wild type (**A,A'**), *adrb2a-/-* (**B,B'**), *pgrmc1-/-* (**C,C'**), and *prp1-/-;prp2-/*- mutants (**D,D'**). (**E-H**) The effect of Aβ^short^ relative to Aβ^rev^ on normalized waking activity (**E and F**) and sleep (**G and H**) during the first day is shown. Each dot represents a single larva normalized to the mean of the Aβ^rev^ control, and error bars indicate ± SEM. The mean difference effect size and 95% confidence interval are plotted below. N = the number of larvae. The wake inducing and sleep suppressing effects of Aβ^short^ are absent in (**E,G**) *adrb2a-/-* and *pgrmc1-/*- but enhanced in *prp1-/-;prp2-/*- mutants (**F,H**). ^ns^p\>0.05, \*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.0001, \*\*\*\*p≤10--5 one-way ANOVA. Data is pooled from n = 2 independent experiments for *adrb2a*-/-and *pgrmc1*-/- and n = 3 for *prp1-/-;prp2-/-*. See also [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}.](elife-53995-fig3){#fig3}

Because the size of oligomeric species in our Aβ^long^ preparation (20--400 nm) falls into the size range that exhibits high-affinity binding to mammalian Prion Protein (PrP) (20--200 nm) and thereby acts to modulate synapses ([@bib17]; [@bib32]; [@bib42]; [@bib61]), we tested whether PrP is instead required for Aβ^long^-induced sleep. After injection of Aβ^long^, *prp1^-/-^;prp2^-/-^* null mutants failed to increase sleep compared to wild-type controls ([Figure 4A--D](#fig4){ref-type="fig"}). The modest reduction of wakefulness induced by Aβ^long^ was even reversed in *prp1^-/-^;prp2^-/-^* mutants, with Aβ^long^ instead significantly increasing wakefulness ([Figure 4C](#fig4){ref-type="fig"}). Thus, while Prps are not required for the wake-inducing effects of Aβ^short^, functional Prp1 and Prp2 are essential for sleep induced by Aβ^long^. Moreover, since *prp* double mutants have exacerbated wakefulness in response to Aβ^short^ injections, the sleep-inducing Prp pathway is likely co-activated along with the wake-promoting pathway by Aβ to partially dampen the behavioral response of wild-type larvae ([Figure 3D and H](#fig3){ref-type="fig"}).

![Sleep induction by Aβ^long^ requires signalling through Prion Protein.\
(**A-B'**) Exemplar 24 hr traces comparing the effects of Aβ^long^ oligomers on average waking activity (**A,B**) and sleep (**A'-B**') versus Aβ^rev^ on wild type (A,A'), and *prp1^-/-^;prp2^-^*^*/*-^ mutant (**B,B'**) backgrounds. (**C-D**) The effect of Aβ^long^ relative to Aβ^rev^ on normalized waking (**C**) and sleep (**D**) on wild type and *prp1^-/-^;prp2^-^*^*/*-^ mutant backgrounds (mixed *prp3* background) during the first day is shown. The activity reducing (**C**) and sleep promoting (**D**) effects of Aβ^long^ are blocked in *prp1^-/-^;prp2^-^*^*/*-^ mutants. \*\*p≤0.01, \*\*\*\*p≤10--5 one-way ANOVA. Data is pooled from n = 3 independent experiments. See also [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}.](elife-53995-fig4){#fig4}

Mutants lacking Aβ targets have altered brain activity in response to Aβ consistent with behavioral effects {#s2-5}
-----------------------------------------------------------------------------------------------------------

If Aβ^short^ interacts with Adrb2a and Pgrmc1 to drive changes in wakefulness, the increased neuronal activity we observed in wild-type larvae after Aβ^short^ injections ([Figure 2A](#fig2){ref-type="fig"}) should also be abolished in the *adrb2a*^-/-^ and *pgrmc1*^-/-^ mutant backgrounds. Consistently, lack of either Adrb2a or Pgrmc1 abolished the neuronal activity-inducing effect of Aβ^short^ ([Figure 5A](#fig5){ref-type="fig"}), as detected by in situ hybridization for *c-fos*. In particular, the neuronal activity observed in the posterior hypothalamus and the dorsal and ventral telencephalon after Aβ^short^ into WT controls was not detected after injection into either *adrb2a^-/-^* or *pgrmc1^-/-^* mutants ([Figure 5A](#fig5){ref-type="fig"}). This result is consistent with Aβ^short^ failing to induce wakefulness in these mutants. Similarly, although Aβ^long^ dampens neuronal activity when injected into wild-type larvae, Aβ^long^ injections into the *prp1^-/-^; prp2^-/-^* double mutants elicited no reduction in *c-fos* expression ([Figure 5B](#fig5){ref-type="fig"}). Instead, *c-fos* expression in the telencephalon and hypothalamus was upregulated relative to reverse injected controls ([Figure 5B](#fig5){ref-type="fig"}), consistent with the increased behavioral wakefulness observed in the *prp* mutants ([Figure 4C](#fig4){ref-type="fig"}). Together, these data are consistent with Aβ^short^ acutely upregulating neuronal activity and behavioral wakefulness through interactions with Adrb2a and Pgrmc1, while Aβ^long^ interactions with Prp drive increased sleep and a global reduction in neuronal activity.

![Neuronal activity after exposure to Aβ preparations is altered in mutants of Aβ binding targets.\
(**A**) After Aβ^short^ injection into WT larvae (top right), *c-fos* is detected in many larval brain areas, including the dorsal and ventral telencephalon and posterior hypothalamus (black arrowheads), but not after injection of Aβ reverse controls (left). In contrast, Aβ^short^ injections into either *adrb2a^-/-^* (middle right) or *pgrmc1^-/-^* mutants (bottom right) do not induce *c-fos* expression. The brains in the middle and lower panels were stained longer than the WT (+/+) brains to ensure detection of weaker expression. D = dorsal, p=Posterior. n = blinded counts of brains with expression pattern/total brains. (**B**) Compared to Aβ^rev^ injections, Aβ^long^ oligomers induce less *c-fos* expression in WT larvae (top panels). In contrast, Aβ^long^ induced relatively increased *c-fos* expression in the telencephalon and posterior hypothalamus (black arrows) in the *prp1^-/-;^ prp2 ^-/-^* double mutants. These Aβ^rev^ and Aβ^long^injectedbrains were stained longer to ensure detection of weaker *c-fos* expression. D = dorsal, p=Posterior.](elife-53995-fig5){#fig5}

Pharmacological blockade of the Prp-mGluR5-Fyn kinase signaling cascade prevents sleep induction by Aβ^long^ {#s2-6}
------------------------------------------------------------------------------------------------------------

One of the advantages of using the zebrafish model system is the ability to perturb Aβ signalling cascades with small molecule inhibitors added directly to the water ([@bib27]; [@bib50]). To further dissect the Aβ^long^-PrP sleep-inducing pathway, we focused on disrupting the putative signalling cascade downstream of Aβ-Prp interactions that lead to synaptic changes in neuronal culture ([@bib61]; [Figure 6A](#fig6){ref-type="fig"}). Consistent with a role for direct Aβ^long^-Prp interactions in sleep, soaking the larvae in Chicago Sky Blue 6B, a small molecule reported to disrupt Aβ-PrP interactions ([@bib51]), significantly abolished the sleep-inducing effect of Aβ^long^ ([Figure 6B and C](#fig6){ref-type="fig"}, S7A and [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). Similarly, pharmacological inhibition of either of the putative Aβ-Prp downstream signalling components Metabotropic Glutamate Receptor 5 (mGluR5) or Fyn kinase ([@bib62]; [@bib61]) significantly blocked the sleep-inducing properties of Aβ^long^ ([Figure 6D and E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}). Both the mGluR5 inhibitor MPEP and the Src-kinase inhibitor saracatinib even resulted in significant sleep reductions after exposure to Aβ^long^. Overall, these results are consistent with the effect of genetic ablation of *prp1* and *prp2*. Thus, both genetic and pharmacological interference with several steps of the Aβ-Prp-mGluR5-Fyn kinase signaling cascade prevents the ability of Aβ^long^ to increase sleep behavior.

![Pharmacological blockade of the Aβ^long^-Prp-mGluR5-Fyn Kinase signaling cascade prevents increases in sleep.\
(**A**) Schematic showing how Aβ--Prp interactions signal through mGluR5 to activate Fyn kinase, leading to synaptic changes ([@bib43]). Small molecules that block each step in the pathway are indicated. (**B**) Representative traces of sleep behavior after Aβ^long^ versus Aβ^rev^ injections in the absence (left) or presence (right) of the Aβ-Prion binding disruptor, Chicago Sky Blue 6B (3 nM). Ribbons represent ± SEM. (**C**) The effect of Aβ^long^ relative to Aβ^rev^ on normalized sleep during the first day in the in the absence or presence of 3 nM Chicago Sky Blue 6B. The data is pooled from n = 2 independent experiments \*\*p≤0.01, one-way ANOVA. (**D**) Representative traces of sleep behavior after Aβ^long^ versus Aβ^rev^ injections in the presence of mGluR5 inhibitor MPEP (5 uM, left) and Fyn Kinase inhibitor saracatinib (300 nM, right). Ribbons represent ± SEM. (**E**) The effect of Aβ^long^ relative to Aβ^rev^ on normalized sleep during the first day in the absence or presence of 5 uM MPEP (left) and 300 nM saracatinib (right). Each dot represents a single larva normalized to the mean Aβ^rev^. Data is pooled from two independent experiments. \*\*p≤0.01, \*\*\*\*p≤10--5 one-way ANOVA. (**F**) The effect of a 1:1 mixture of Aβ^long^ to Aβ^short^ relative to single injections of Aβ^rev^, Aβ^short^, and Aβ^long^ on normalized sleep during the first day. The data is pooled from n = 4 independent experiments. (**G**) A bi-directional model for sleep/wake regulation by Aβ. In wild-type animals (centre), injection of Aβ^short^ species signal through Adrb2a/Pgrmc1 to drive wakefulness while Aβ^long^ oligomers signal via Prp to induce sleep. In mutants that lack Prp (left), only Aβ^short^ species (as shown by the overlapping distributions) remain to inhibit sleep with no residual Aβ^long^ oligomers to stimulate the sleep-inducing pathway to counteract wake-inducing signals. Thus *prp1^-/-^; prp2^-/-^* mutants have enhanced wakefulness in response to Aβ. Conversely, mutants that lack Adrb2a/Pgrmc1 (right), retain only the sleep-promoting Aβ pathway and fail to increase wakefulness in response to Aβ^short^. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.](elife-53995-fig6){#fig6}

Aβ^short^ and Aβ^long^ affect sleep through distinct neuronal/molecular pathways {#s2-7}
--------------------------------------------------------------------------------

Although long and short oligomers require different receptors to affect behavior, they may act within the same neuronal circuit signalling cascade. If so, one phenotype should predominate over the other when the two oligomers are co-administered. Alternatively, oligomers may signal through parallel signalling circuits to bi-directionally modulate sleep in an additive manner. To test this, we co-injected Aβ^short^ and Aβ^long^ in a 1:1 ratio and compared the sleep phenotype to injection of either oligomer alone. As expected, Aβ^short^ alone reduced sleep and Aβ^long^ alone increased sleep. In contrast, co-injection of both Aβ^short^ and Aβ^long^ resulted in an intermediate phenotype that is indistinguishable from control injections of Aβ^rev^ ([Figure 6F](#fig6){ref-type="fig"}), suggesting that the effects of Aβ^short^ and Aβ^long^ are additive and likely act through distinct neuronal circuits or signaling cascades to modulate sleep.

Considering this result is aligned with the genetic and pharmacological data, we propose a bi-directional model of Aβ sleep regulation in which Aβ^short^ and Aβ^long^ act through distinct receptors and neuronal pathways to independently modulate behavioral state ([Figure 6G](#fig6){ref-type="fig"}). In this model, the presence of both oligomers leads a balance of signaling through sleep-promoting and sleep-inhibiting pathways, resulting in little or no change in behavior. Tipping the balance from one oligomeric state to the other leads to either the sleep activating or the sleep inhibiting pathway to predominate.

Discussion {#s3}
==========

Previous studies have suggested that changes in sleep during AD may further accelerate Aβ accumulation and neuronal damage, creating a vicious cycle that leads to further neuronal dysregulation and increased sleep-wake cycle abnormalities ([@bib52]). Our results show that, depending on its oligomeric form, Aβ can acutely increase or decrease sleep and wake behaviors and brain states through behaviorally relevant molecular targets and independently of neuronal cell death. The exogenous application of Aβ oligomers in our experiments limit the conclusions we can draw about endogenous functions of Aβ, which in vivo may present with different structure, local concentrations, and kinetics. However, the bi-directional Aβ modulation of sleep and wakefulness ([Figure 6G](#fig6){ref-type="fig"}) predicts that alterations to the relative concentrations of different Aβ oligomeric forms during healthy aging and AD disease progression will have opposing consequences on sleep and wake behavior.

Distinct molecular pathways for Aβ sleep-wake regulation {#s3-1}
--------------------------------------------------------

We found that Aβ^short^-triggered wakefulness required intact Adrb2a and Pgrmc1, while Aβ^long^-induced sleep required functional Prp signalling. These data are consistent with a model in which Aβ directly binds to these targets to modulate downstream signaling cascades that ultimately affect neuronal circuits that regulate behavioral state. Our results match well with previous reports demonstrating binding preferences of Aβ dimers, trimers, and 56 kDa oligomers for different targets in vitro. For example, Aβ dimers, which have been detected in the brains of AD patients ( [@bib63]), have been shown to directly bind human ADRB2 with high-affinity, causing increased calcium influx and neuronal hyper-activation in rat prefrontal cortical slices ([@bib67]). PGRMC1 can be activated by AD brain extracts ([@bib22]) and also has shown preferential binding for 50--75 kDa Aβ species in vitro ([@bib21]). Both types of shorter Aβ species that bind to ADRB2 and PGRMC1 fall within the size ranges that induce Adrb2a- and Pgrmc1-dependent wakefulness in zebrafish larvae. Our results are also consistent with studies that have identified PrP as a direct binding partner ([@bib32]) for longer Aβ-oligomers of 20--200 nm in length ([@bib42]), the size range of our sleep-inducing Aβ^long^ preparation. In neuronal culture and slice preparations, longer Aβ-oligomers trigger reduction of synaptic strength ([@bib32]) via a Prp signaling cascade through mGluR5 and Fyn kinase activation ([@bib61]). Similarly, we found that pharmacological blockade of either the direct Aβ-Prp interaction (with Chicago Sky Blue 6B), mGluR5 signalling (with MPEP), Fyn kinase activity (with saracatinib), or by mutation of the Prp receptors prevented the widespread reduction of neuronal activity and increase in sleep that was induced by longer Aβ-oligomers.

Although triggering neuronal and behavioral changes through distinct molecular pathways, several aspects of Aβ's effects on sleep-wake regulation remain to be elucidated. For example, the elimination of either Adrb2a or Pgrmc1 is sufficient to fully prevent Aβ^short^-induced wakefulness. This suggests that Adrb2a and Pgrmc1 function in the same molecular pathway, and signaling by Aβ on either alone is insufficient to modulate behavior. Not much is known about how these two receptors interact with one another, but at least one study ([@bib53]) has suggested they can directly physically interact. Whether Aβ^short^ binds both receptors to affect behavior or whether one receptor is an obligate component of the other's ability to transmit Aβ signals is currently unclear. It also remains unclear if the Aβ^short^-Adrb2a/Pgrmc1 wake pathway and the Aβ^long^-Prp sleep pathway occur in the same or different sets of neurons to modulate behavior, as these receptors have widespread expression in zebrafish ([@bib10]; [@bib37]; [@bib56]; [@bib59]; [@bib66]), although our co-injection experiment suggests they act on parallel neuronal circuits. Numerous wake- and sleep-promoting neuronal populations that could serve as neuronal targets for these signalling cascades to drive changes in behavioral state have been uncovered in zebrafish ([@bib5]). Future experiments will be needed to tease out the neuronal components involved, for example by replacing functional receptors into candidate neurons in otherwise mutant animals and rescuing the responses to Aβ, or by mutating receptors selectively in cell types with conditional genetics.

Altered Aβ oligomeric ratio---implications for sleep in health and AD {#s3-2}
---------------------------------------------------------------------

Our model investigates alterations in sleep/wake behavior due to acute changes in exogenously delivered Aβ levels. Thus, it is possible that the sleep/wake effects observed in our study may be different from those observed when Aβ fluctuates over 24 hr or when it is chronically accumulating as in AD. However, our model predicts that alterations to the ratio of Aβ oligomeric forms present in the brain could have differential effects on sleep-wake regulation, as the balance between sleep- and wake- promoting Aβ signals is tilted to favour one pathway over the other ([Figure 6G](#fig6){ref-type="fig"}).

Given the natural daily increase in Aβ secretion during wakefulness and increased levels of Aβ clearance during sleep ([@bib69]), changes in extracellular Aβ levels could sculpt behavior over the normal 24 hr circadian cycle. As Aβ burden is acutely increased by sleep deprivation ([@bib54]), perturbations to the normal sleep-wake cycle may feedback on behavior through altered Aβ signaling. Other phenomena have been reported to alter Aβ generation and fibrilization over short time-scales. For example, temperature changes in the physiological range (35--42°C) have been reported to significantly affect Aβ oligomerization ([@bib16]), suggesting that either the natural daily fluctuation in body temperature (in humans, up to 2°C) or the induction of a fever can promote changes in amyloidogenic Aβ generation ([@bib58]). In addition, Aβ can act as an antimicrobial peptide ([@bib29]; [@bib55]), and microbial infection can trigger Aβ fibrilization ([@bib12]). Considering that infection and fever are also potent drivers of sleep ([@bib19]), the sleep-inducing Aβ-Prp signaling pathway we identified here could mediate recovery sleep during illness\-- a hypothesis for future investigation.

On longer timescales, the amount and type of Aβ oligomeric species (including dimers, cross-linked dimers, trimers, and 56 kDa oligomers) found in healthy brains change across the human life cycle ([@bib34]) and are heterogeneous and elevated in AD patients ([@bib21]; [@bib28]). Although the precise makeup of Aβ species present in healthy and AD brains has remained difficult to quantify ([@bib7]), some studies have indicated that short (dimers, trimers) Aβ oligomers are more enriched in the early, mild cognitive impairment (MCI) stages of AD, while longer oligomers predominate in the CSF at later clinical stages of AD ([@bib11]). Similarly, AD progression is associated with increasingly large disruptions in sleep patterns, with patients exhibiting high levels of sleep fragmentation, a lack of circadian rhythm, night-time insomnia and irregular daytime napping throughout the day ([@bib64]). One possibility consistent with our data is that sleep symptoms of both normal aging and AD may reflect changes in Aβ burden that lead to an altered balance in sleep- and wake-promoting signaling cascades. These signaling molecules might therefore be potential therapeutic targets for treating disrupted sleep early in AD progression, which may in turn slow disease progression.

Materials and methods {#s4}
=====================

See the Key Resources Table (Appendix 1---key resources table) for details of reagents.

Zebrafish strains and husbandry {#s4-1}
-------------------------------

Zebrafish (*Danio rerio*) were raised under standard conditions at 28°C in a 14:10 light:dark cycle and all zebrafish experiments and husbandry followed standard protocols of the UCL Zebrafish Facility. AΒ, TL and AΒxTup wild-type strains were used in this study. *prp1* (ua5003/ua5003), *prp2* (ua5001/5001), *adrb2a (*u511/u511) and *pgrmc1 (*u512/u512) mutants were outcrossed multiple times, and *pgrmc1* F2 and *adrb2a* F2 and later generations were used for behavior. Ethical approval for zebrafish experiments was obtained from the Home Office UK under the Animal Scientific Procedures Act 1986 with Project licence numbers 70/7612 and PA8D4D0E5 to JR.

Aβ preparations {#s4-2}
---------------

HFIP treated Aβ42 peptide (JPT Peptide Technologies) and Aβ42--1 reversed peptide (Sigma) were dissolved in DMSO, vortexed occasionally for 12 min at room temperature and sonicated for 5 min to obtain 100 μM solution. The stock solutions were aliquoted as 5 μl in individual tubes and are kept are −80°C. 1 μl of the 100 μM stock was diluted in (Phosphate buffered saline) PBS to yield 10 μM solutions which were incubated at 4°C, 25°C or 37°C for 24 hr ([@bib30]; [@bib45]; [@bib68]). 1 hr before injecting, this stock was diluted to 10 nM using 1:10 serial dilutions in PBS and kept at the respective temperature (4°C, 25°C, 37°C) until injecting.

Transmission Electron Microscopy (TEM) {#s4-3}
--------------------------------------

1 μl of (4°C, 25°C or 37°C incubated) 10 μM Aβ solution was loaded onto formvar/carbon coated 300 mesh grids from Agar Scientific. The grid was washed twice in 20 mM phosphate buffer for 10 s and negatively stained in 2% aqueous uranyl acetate for 30 s. After drying for 2--3 days, samples were imaged using a Phillips TEM. At least five micrographs were used for each condition to blindly measure the length of the Aβ42 oligomeric structures using at least 30 measurements/condition. Using FIJI, 30--50 measurements were taken for each condition by drawing a free-hand line on the fibril, which was then scaled using the scale bar.

Heart injections {#s4-4}
----------------

Injections were carried out blindly with a Pneumatic PicoPump (WPI) and glass capillary needles (Science Products Gmbh) prepared with a Micropipette Puller (Shutter Instruments). Five dpf larvae were anesthetized using 4% Tricaine (42 mg/L, Sigma) 30 min before injections. Larvae were immobilized in 1.8% low melting point agarose (ThermoFischer) in fish water on their sides on a slide. 1 nL of Aβ (10 nM starting concentration) was injected into the heart chamber of the fish along with a high molecular weight fluorescent dye (2000 kDa dextran-conjugated FITC (3 mg/ml, Sigma). We estimate that 1 nl of a 10 nM Aβ injection into a \~ 3.01 (±0.16) x10^8^ µm^3^(285--317 nL) 5dpf larva yields a final monomeric brain/CSF concentration of \~28--32 pM. The success of the injection was checked under a standard fluorescent scope by the presence of fluorescence in the heart of the animal. Larvae were transferred to fresh fish water for 20 min to recover from Tricaine and transferred to sleep/wake behavior box. For drug blocking experiments, zebrafish larvae were soaked into 3 nM Chicago Sky Blue 6B (Sigma), 5 μM MPEP (Cambridge Biosciences), or 300 nM Saracatinib (Generon) 1 day before the injections (from 4 to 5 dpf). Fluorescently tagged HiLyte Fluor 647-labeled Aβ42 (Eurogentech LTD) was injected at 10 µM.

Behavioral experiments {#s4-5}
----------------------

Larval zebrafish behavioral experiments were performed and analysed as described ([@bib50]). Briefly, 5 dpf larvae were transferred to 96 square-well plates and continuously illuminated with IR and white lights from 9 am to 11 pm in a Zebrabox (Viewpoint life sciences) for 24--48 hr. The movement of each larva was measured and duration of movement was recorded with an integration time of 10 s. Data were processed according to [@bib50], and statistical tests were performed using MATLAΒ. Mutant larval zebrafish experiments were performed on siblings from heterozygous in-crosses, differing only in the mutation of the specific gene and genotyped at the end of the experiment.

Dark pulse experiments {#s4-6}
----------------------

Larvae were placed in the behavior tracking boxes, and two or three dark pulses for 10 min with a 2--4 hr interval were introduced in four independent experiments. For data analysis, only the dark pulses after the acclimatization period in the late afternoon were combined for each genotype.

In situ hybridization {#s4-7}
---------------------

RNA in situ hybridization (ISH) to detect *c-fos* and *galanin* was performed as described ([@bib60]). Zebrafish larvae were fixed in 4% paraformaldehyde in PBS at 4°C overnight. A template for in vitro transcription was generated by PCR using a reverse primer that contains a T7 promoter sequence 5'-TAATACGACTCACTATAGGG-3' from cDNA. A digoxygenin (DIG)-labelled antisense RNA probe was synthesized using the DIG labelling kit (Roche) and T7 RNA polymerase according to the manufacturer's recommendations. The probe was detected with anti-DIG-AP antibody (1:2,000, Roche) and nitro-blue tetrazolium chloride (NBT)/5-bromo-4-chloro-3′-indolyphosphate (BCIP) substrate (Roche) according to published protocols. To detect the differences in expression between the mutant backgrounds and WTs after Aβ^short^ and Aβ^long^ injection, larvae were incubated and washed in the same tubes throughout the ISH procedure to avoid staining artefacts. To do this, larvae from different genotypes were marked by cutting the tail to allow identification after ISH. The brains were exposed by dissection, keeping the brain and spinal cord intact. Embryos were stored in 60% glycerol/PBS for imaging.

Baseline c-fos ISH {#s4-8}
------------------

Zebrafish larval siblings were kept in 14:10 day/night normal or reverse-cycle incubators. 50 larvae were collected at each time point (ZT1, ZT13, and ZT19) and fixed in 4% paraformaldehyde in PBS overnight. RNA in situ hybridization (ISH) to detect *c-fos* was performed as described ([@bib60]).

KASP genotyping {#s4-9}
---------------

For rapid genotyping of mutant zebrafish harbouring the *adrb2aΔ8* and *pgrmc1Δ16* alleles, a mutant allele-specific forward primer, a wild-type allele-specific forward primer and a common reverse primer were used (LGC Genomics). The primer sequences were targeted against the following:

1.  adrb2a

2.  5'TTTTACTACTTACTGTTTGCACAAACCTATGTTAACTGTGTTAACGTGTTTTCTTCTGCTTTTCTTTCTTGATCTCTGTCAGGTCATGGGAAACATAAGGTCCTCAATACC**\[CGAAGATC/-\]**TTATCTGTCCAAACAATACTAATGCCTCCACCAAAAGCGAACTACAGATGACAGTGCTGGGCACACTCATGTCCATTCTTGTCTTGATCATCGTCTTTGGCAATGTGATGGTGATTACAGCCA-3'

3.  pgrmc1

4.  5'ATGGCTGAAGAAGCAGTCGAGCAAACTTCTGGAATCCTTCAGGAAATTTTCACGTCGCCACTGAACATCAGTTTGCTATGTCTTTGTTTGTTCCTACTTTACAAAATCATCCGCGGAGACAAGCC**\[TGCAGACTATGGCCCG/-\]**GYTGAGGAGCCGCTGCCCAAACTCAAGAAAAGAGATTTYACTTTAGCAGATCTGCAAGAGTACGATGGACTGAAAAACCCAAGAATCCTGATGGCTGTCAACGGG-3'

where \[x/-\] indicates the indel difference in \[WT/mutant\]. PCR amplification was performed using KASP Master mix (LGC Genomics) according to the manufacturer's instructions. Fluorescence was read on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) and the allelic discrimination plot generated using Bio-Rad CFX Manager Software.

Time lapse confocal microscopy {#s4-10}
------------------------------

Three Casper larvae at five dpf were mounted dorsally on a slide in 1.5% agarose. 10 nl of Aβ42-Hi488 was intra-cardiac injected to embryos, control fish were untreated. Fish were imaged for 6 min taking 2-μm-thick stacks through the whole brain using a confocal microscope (Leica SP8). Each fish was imaged every 20 min for 8 hr.

pERK/tERK staining and activity Mapping {#s4-11}
---------------------------------------

Larvae were fixed overnight at 4°C in 4% paraformaldehyde (PFA) and 4% sucrose in PBS; permeabilized 45 min in 0.05% trypsin-EDTA on ice; blocked 6 hr at room temperature (RT) in phosphate buffered saline plus 0.05% Triton (PBT) plus 2% normal goat serum, 1% BSA, and 1% DMSO; and then incubated over sequential nights at 4°C in primary antibodies (Cell Signaling Technology 4370 and 4696; 1:500) and secondary antibodies conjugated with Alexa fluorophores (Life Technologies; 1:200) in PBT plus 1% BSA and 1% DMSO.

Larvae were mounted in 1.5% low melt agarose and imaged with a custom two-photon microscope (Bruker; Prairie View software) with a 203 water immersion objective (Olympus).

Images were noise filtered using a custom MATLAB (The MathWorks) scripts and registered into Z-Brain using the Computational Morphometry Toolkit (<http://www.nitrc.org/projects/cmtk/>) with the command string: -a -w -r 0102 l af -X 52 C 8 G 80 R 3 -A '--accuracy 0.4 --auto-multi-levels 4' -W '--accuracy 1.6' -T 4. Registered images were prepared using a custom MATLAB/MIJ (<http://bigwww.epfl.ch/sage/soft/mij/>) script to downsize, blur, and adjust the maximum brightness of each stack to the top 0.1% of pixel intensities to preserve dynamic range. Activity maps were generated using MATLAB scripts ([@bib48]).

Crispr/Cas9 mutant generation {#s4-12}
-----------------------------

The CRISPR design tool CHOPCHOP (<http://chopchop.cbu.uib.no>) was used to identify a target region in zebrafish *adrb2a* and *pgrmc1* ([@bib31]). The gene-specific oligomers were ordered from Thermofisher including the 5' and 3' tags:

1.  For *adrb2a*:

2.  5'ATTTAGGTGACACTATAGTTTGGACAGATAAGATCTTGTTTTAGAGCTAGAAATAGCAAG-3'

3.  For *pgrmc1*:

4.  5'ATTTAGGTGACACTATATGCAGACTATGGCCCGGTTGGTTTTAGAGCTAGAAATAGCAAG-3'

5.  Constant oligomer:

6.  5'AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCT AGCTCTAAAAC-3'

The constant oligomer and the gene-specific oligomer were annealed on a PCR machine and filled in using T4 DNA polymerase (NEB) ([@bib15]). The template was cleaned up using a PCR clean-up column (Qiaquick) and the product was verified on a 2% agarose gel. The sgRNA was transcribed from this DNA template using Ambion MEGAscript SP6 kit ([@bib15]). Cas9 mRNA and the purified sgRNA were co-injected into one-cell stage embryos at a concentration of 200 ng and 100 ng per embryo, respectively.

Caspase-3 staining {#s4-13}
------------------

5dpf larvae that were injected with Aβ oligomers or soaked in Camptothecin (1 µM; Sigma Aldrich) were fixed 5 hr after injection/drug treatment in 4% PFA and kept overnight at 4°C. Brains were dissected and dehydrated the next day and were washed three times in PDT buffer (0.3 Triton-X in PBST with 1% DMSO) and incubated with Caspase-3 antibody (1:500; BD Biosciences) at 4°C. The brains were incubated with Alexa Fluor 568 goat anti-rabbit antibody (1:200; Invitrogen) next day at 4°C overnight and imaged using a confocal microscope.

Statistical analyses {#s4-14}
--------------------

For data analyses, we used a Gardner-Altman estimation plot, which visualizes the effect size and displays an experimental dataset's complete statistical information ([@bib18]). The bootstrapped 95% confidence interval (CI) was calculated from 10,000 bootstrapped resamples ([@bib18]).

Details of statistics used in each panel are also described in the figure legend. For multiple comparisons, data was first tested for normality by the Kogloromov-Smirnov (KS) statistic and extreme outliers were discarded by Grubb's test (p≤0.01). Those that violated normality were analysed with the non-parametric Kruskal-Wallis test, with either Tukey-Kramer or Bonferonni post hoc testing; otherwise, data was analysed with one-way ANOVA followed by Tukey's post-hoc testing. For dose response curves, a two-way ANOVA was performed to test the interaction effects between preparation type and dose. For return to baseline statistics, paired t-tests were performed. Survival curves were analysed with Kaplan-Meier log rank test. All statistical tests and graphs were generated in MATLAB (R2015a) loaded with the Statistical Toolbox. Injection and tracking experiments were performed blinded.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource   Designation                                              Source or reference                                         Identifiers                                                                      Additional information
  ------------------------------------ -------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Gene (*Danio rerio*)\                *prp1*                                                   [@bib33]\                                                   ZFIN ID: ZDB-GENE-041221-2\                                                       
                                                                                                PMID:[29903907](https://pubmed.ncbi.nlm.nih.gov/29903907)                                                                                    

  Gene (*Danio rerio*)\                *prp2*                                                   [@bib13]\                                                   ZFIN ID: ZDB-GENE-041221-3\                                                      
                                                                                                PMID:[23523635](https://pubmed.ncbi.nlm.nih.gov/23523635)                                                                                    

  Gene (*Danio rerio*)\                *adrb2a*\                                                This paper                                                  ZFIN ID: ZDB-GENE-100414-3\                                                      

  Gene (*Danio rerio*)\                *pgrmc1*\                                                This paper                                                  ZFIN ID: ZDB-GENE-041114-91\                                                     

  Strain background\                   AB                                                       UCL Fish Facility                                                                                                                            
  (*Danio rerio*)\                                                                                                                                                                                                                           

  Strain background\                   TL                                                       UCL Fish Facility                                                                                                                            
  (*Danio rerio*)\                                                                                                                                                                                                                           

  Strain background\                   ABxTup                                                   UCL Fish Facility                                                                                                                            
  (*Danio rerio*)\                                                                                                                                                                                                                           

  Strain (*Danio rerio*)\              *prp1* (ua5003/ua5003) mutant                            [@bib33]\                                                   ZFIN ID: ZDB-ALT-181113-1                                                        
                                                                                                PMID:[29903907](https://pubmed.ncbi.nlm.nih.gov/29903907)                                                                                    

  Strain (*Danio rerio*)\              *prp2* (ua5001/5001) mutant                              [@bib33]\                                                   ZFIN ID: ZDB-ALT-130724-2                                                        
                                                                                                PMID:[29903907](https://pubmed.ncbi.nlm.nih.gov/29903907)                                                                                    

  Strain (*Danio rerio*)\              *adrb2a* (u511/u511) mutant\                             This paper                                                                                                                                   Allele will be added to ZFIN upon publication acceptance

  Strain (*Danio rerio*)\              *pgrmc1* (u512/u512) mutant\                             This paper                                                                                                                                   Allele will be added to ZFIN upon publication acceptance

  Antibody                             anti-DIG-AP antibody (Sheep) polyclonal                  Roche                                                       Cat \# 14608125; RRID:[AB_2734716](https://scicrunch.org/resolver/AB_2734716)\   (1:2000)

  Antibody                             anti-Active Caspase 3\                                   BD Biosciences\                                             Cat \# 559565; RRID:[AB_397274](https://scicrunch.org/resolver/AB_397274)\       (1:500)
                                       (Rabbit)\                                                                                                                                                                                             

  Antibody                             p44/42 MAP Kinase (L34F12) Mouse mAb\                    Cell Signaling\                                              Cat \# 4696; RRID:[AB_390780](https://scicrunch.org/resolver/AB_390780)\        (1:500)

  Antibody                             Phospho-p44/42 MAPK(Erk1/2)(Thr202/Tyr204) Rabbit mAb\   Cell Signaling\                                             Cat \# 4370; RRID:[AB_2315112](https://scicrunch.org/resolver/AB_2315112)\       (1:500)

  Antibody                             Alexa Fluor 568 goat anti-mouse, polyclonal\             Thermo Fisher Scientific\                                   Cat \# A-11031; RRID:[AB_144696](https://scicrunch.org/resolver/AB_144696)\      (1:200)

  Antibody                             Goat anti-Rabbit IgG Alexa 488, polyclonal\              Thermo Fisher Scientific\                                   Cat \# A-11034; RRID:[AB_2576217](https://scicrunch.org/resolver/AB_2576217)\    (1:200)

  Sequence-based reagent               *galanin* probe                                          [@bib8]\                                                    Plasmid for galanin ISH riboprobe                                                
                                                                                                PMID:[28648499](https://pubmed.ncbi.nlm.nih.gov/28648499)                                                                                    

  Sequence-based reagent               *c-fos* probe                                            [@bib49]\                                                   Plasmid for c-fos ISH riboprobe                                                  
                                                                                                PMID:[31537465](https://pubmed.ncbi.nlm.nih.gov/31537465)                                                                                    

  Sequence-based reagent               *adrb2a*                                                 This paper                                                  Gene-specific oligomer for CRISPR                                                5'ATTTAGGTGACACTATAGTTTGGACAGATAAGATCTTGTTTTAGAGCTAGAAATAGCAAG-3'\

  Sequence-based reagent               *pgrmc1*                                                 This paper                                                  Gene-specific oligomer for CRISPR                                                5'ATTTAGGTGACACTATATGCAGACTATGGCCCGGTTGGTTTTAGAGCTAGAAATAGCAAG-3'\

  Sequence-based reagent               gRNA constant region                                     Thermofisher\                                               Constant oligomer for CRISPR                                                     5'AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCT AGCTCTAAAAC-3'

  Peptide, recombinant protein         Beta-Amyloid (1-42); HFIP treated\                       JPT Peptide Technologies                                     Cat\# SP-Ab-07_0.5\                                                             

  Peptide, recombinant protein         Amyloid β 42-1 reverse human\                            Sigma Aldrich                                               Cat\# SCP0048\                                                                   

  Peptide, recombinant protein         ß-Amyloid (1-42), HiLyte Fluor 647-labeled               Eurogentech LTD                                             Cat\# AS-64161\                                                                  

  Commercial assay or kit              T4 DNA polymerase                                        NEB                                                         Cat\# M0203S\                                                                     

  Commercial assay or kit              PCR clean-up column kit                                  Qiaquick                                                    Cat\# 28104\                                                                      

  Commercial assay or kit              Ambion MEGAscript SP6 kit                                Ambion                                                      Cat\# AM1330\                                                                    

  Chemical compound, drug              2000 kDa dextran-conjugated FITC                         Sigma Aldrich                                               Cat\# 52471\                                                                     3 mg/ml

  Chemical compound, drug              Chicago Sky Blue 6B                                      Sigma Aldrich                                               Cat\# C8679\                                                                     3 nM

  Chemical compound, drug              MPEP                                                     Cambridge Biosciences                                       Cat\# CAY14536\                                                                  5 μM

  Chemical compound, drug              Saracatinib                                              Generon                                                     Cat\# A2133\                                                                     300 nM

  Chemical compound, drug              Pentylenetetrazol (PTZ)\                                 Sigma Aldrich                                               Cat\# P6500\                                                                     10 mM

  Chemical compound, drug              Camptothecin                                             Sigma Aldrich                                               Cat\# 208925\                                                                    1 uM

  Software, algorithm                  Sleep analysis2                                          [@bib50]\                                                                                                                                    
                                                                                                PMID:[21111222](https://pubmed.ncbi.nlm.nih.gov/21111222)                                                                                    

  Software, algorithm                  Dabest estimation plots                                  [@bib18]\                                                                                                                                    
                                                                                                PMID:[31217592](https://pubmed.ncbi.nlm.nih.gov/31217592)                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10.7554/eLife.53995.sa1

Decision letter

Sehgal

Amita

Reviewing Editor

Howard Hughes Medical Institute, University of Pennsylvania

United States

Musiek

Erik Steven

Reviewer

Washington University School of Medicine in St. Louis

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript provides new insight into mechanisms by which oligomers of amyloid beta might affect sleep. While Alzheimer\'s Disease is linked to sleep disruption, the nature of the interaction is still unclear. Using a zebrafish model, the authors show that short and long amyloid oligomers interact with different binding partners to decrease or increase sleep respectively.

**Decision letter after peer review:**

Thank you for submitting your article \"Bi-directional modification of sleep and wake by amyloid beta oligomers\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Michael Eisen as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Erik Musiek (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers found the manuscript of interest and considered it a potentially important conceptual advance. However, they had a few concerns, which would need to be addressed for further consideration at *eLife*:

The model is based on intracardiac injection of Aβ, so the phenotypes result from exogenous expression/overexpression. Given this, the authors should refrain from drawing conclusions about endogenous Aβ. At the same time, the manuscript would benefit from minimal characterization of the endogenous molecules. For instance, is there a rhythm of Aβ expression over the sleep:wake cycle?

The fish undergo anesthesia and heart perforation and are recorded a few hours later. What are the controls for handling, surgical stress, and confounds of prior anesthesia? On a related note, can the authors exclude toxicity, which could affect motion? They address this point by showing *c-fos* and ERK staining, but many different patterns are observed and none are compared to staining under baseline sleep:wake conditions. It is also disturbing that the *c-fos* expression is so widespread. The reversibility of the effect is important and the role of specific molecules is interesting, but these still do not demonstrate impact on wake or sleep regulation per se.

Given that AD brains likely have oligomers of all sizes, it would be good to know what happens when short and long oligomers are infused together.

Reviewer 1:

There is a growing appreciation about the fundamental bidirectional link between sleep and Alzheimer\'s disease. Here Rihel and colleagues use a zebrafish model coupled to the injection of amyloid beta oligomers (the initiating pathogenic species for AD) to examine the link between Aβ and sleep. They demonstrate that the length of the oligomers determines whether Aβ induces wake (short Aβ) or sleep (long Aβ), providing novel insights into the role of different forms on sleep/wake. Importantly, they extend their findings to reveal novel molecular insights into the mechanisms into how Aβ exerts these sleep/wake effects. Overall, the findings make an important advance that will be of interest to the broad *eLife* readership.

I have one significant concern relating to claims that these studies reveal novel functions for the endogenous Aβ. A key missing experiment in this regard is manipulation of the endogenous Aβ gene/protein (or even assessment of endogenous Ab) and thus it is unclear if exogenous (intracardiac) injection of Aβ faithfully reproduces how an endogenous neuronal pathway would deliver Aβ in terms of location, local concentrations and kinetics.

I think the findings are significant and important on their own without having to make this claim which in this case is highly speculative. I would suggest either addressing experimentally or rewording and de-emphasizing this point in the text to make clear the speculative possibilities. In any case, these shortcomings should be more forthrightly noted.

Reviewer 2:

The use of zebrafish to investigate the role of beta amyloid polymers on sleep/wake regulation is potentially interesting as AD patients suffer from insomnia. Here Ozcan and colleagues inject oligomers synthesized in vitro into the fish neonate hearts and fish motion was then recorded and used as a proxy for sleep and wake states. The authors found a correlation between the polymer length and the impact on fish motor and brain activity.

While the findings are potentially interesting, several points are unclear if concerning to the reviewer:

1\) First, all the experiments and interpretations rely on overexpression of Aβ polymers, there is no description or investigation in this study of the normal baseline of Aβ accumulation in this species. One would expect to see such data in Figure 1 and Figure 1---figure supplement 1 for example. Is there in fish a night vs. day, sleep vs. night rhythm of Aβ accumulation/expression?

2\) The fish undergo anesthesia and heart perforation and are recorded a few hours later. How do handling, surgical stress, and confounds of prior anesthesia can be eliminated from \"sleep-wake\" data interpretation?

3\) It is hard for the reader to distinguish a specific effect on sleep/wake. Increased or decreased motion could be due to toxicity or specific stimulation of neuronal circuits due to non-physiological presence of exogenous oligomers. The authors try to tackle this issue with *c-fos* and ERK staining, but Figure 2 shows at least 6 different staining patterns, none of them compared to a sleep/wake baseline of staining. It is quite worrisome to see such a broad over expression of *c-fos* throughout the brain when Aβ is accumulated. Are the fish having a seizure?

Toxicity could lead to reduced motion and even if it\'s reversible it can still be transient toxicity until oligomers are washed out. Hyperactivity could be due to aspecific overstimulation of neurons as illustrated by *c-fos* and ERK staining.

4\) Injections in mutant backgrounds indeed show some specificity in binding/interaction but still it does not demonstrate that the impact is on wake or sleep regulation per se. Again only motion or broad brain staining (at one time point...) are shown. An alternative interpretation is that adrb2a, pgrmc, prp1 can indeed bind Aβ but relay the toxic or aspecific impact of oligomers over expression in a brain that normally does not accumulate such molecules.

This study has the potential to be extremely interesting but many controls and demonstration of endogenous Aβ role on sleep-wake cycle are needed.

Reviewer 3:

The authors report the use of a novel model of intracardiac infusion of Aβ peptides in zebrafish larvae to study the effects of Aβ on sleep and neuronal activity. They provide convincing data that preparations of shorter Aβ oligomers induce neuronal activity and decrease sleep, while longer oligomers suppress neuronal activity and decrease sleep. They then delete known Aβ receptor proteins, and show that the effects of Aβ-short can be block by deletion of Adrb2 and Pgrmc1, while the effects of Aβ-long are blocked by prion protein deletion, or specific drugs. This is a unique system and method for administering Aβ that is quite powerful, and the experiments are rigorous and generally use multiple converging approaches (for instance genetic+pharmacologic) to support their findings. The reversibility of the effect, as well as blockade with specific pharmacological agents suggests that these are not non-specific toxic events. The findings provide a framework with which to potentially test other neurodegenerative proteins (such as a-syn), and to inform similar studies in mammalian systems.

1\) While the experiments are well performed and the data intrinsically consistent, the applicability to mammals (and humans) is a consideration. Infusion of Aβ into the heart of larvae is a highly artificial system, and events that occur during sudden changes in Aβ levels may be different that those observed when Aβ is chronically present (as in AD). For example, infusion of Aβ peptide into the brain of mice or rats can induce acute, local neurodegeneration that is not observed in APP transgenic mice with chronically elevated Aβ levels. This is a fundamental shortcoming of the model, and there is little that can be done to address it, but it should be perhaps mentioned in the Discussion.

2\) The implications of this bidirectional effect of short and long oligomers for sleep phenotypes in AD are also a bit unclear, as oligomers of all sizes are likely present in AD brain (though perhaps in different ratios as the disease progresses). It would be helpful to determine which pathway is dominant when both short and long oligomers are infused together, perhaps in different ratios. This is the only experiment I would request.

10.7554/eLife.53995.sa2

Author response

> The reviewers found the manuscript of interest and considered it a potentially important conceptual advance. However, they had a few concerns, which would need to be addressed for further consideration at eLife:
>
> The model is based on intracardiac injection of Aβ, so the phenotypes result from exogenous expression/overexpression. Given this, the authors should refrain from drawing conclusions about endogenous Aβ.

We have modified the text throughout to be clearer about this limitation of our methodology. We address this in our detailed responses to each reviewer's comments.

> At the same time, the manuscript would benefit from minimal characterization of the endogenous molecules. For instance, is there a rhythm of Aβ expression over the sleep:wake cycle?

This point is extremely difficult to address in zebrafish currently. To our knowledge, a daily rhythm of Aβ has only been detected in measurement of the ISF/CSF (Holth et al., 2019; Kang et al., 2009; Roh et al., 2012), but this rhythm is not detected in whole tissue homogenates in mammals e.g.(Kang et al., 2009). Since the total CSF in one zebrafish larval brain is only \~6.5 nl (Fame et al., 2016), and typical experiments can only remove 1-2 nl of fluid per animal, it was not feasible to extract CSF from 900-5000 larvae to obtain \~5 μl of CSF for a single timepoint analysis, let alone the numbers that would be needed across 24hr. We therefore attempted to detect Aβ using whole tissue homogenates, but the sensitivity even for this method was not sufficient for us to detect Aβ in fish ([Author response image 1](#sa2fig1){ref-type="fig"}). Potentially higher sensitivity kits were to be tried, but the global pandemic prevented those from being delivered before we were ordered shut.

![A Western blot against Aβ42 is unable to detect a band in homogenates from 35-50 zebrafish larvae or from an adult brain.](elife-53995-resp-fig1){#sa2fig1}

> The fish undergo anesthesia and heart perforation and are recorded a few hours later. What are the controls for handling, surgical stress, and confounds of prior anesthesia?

We address this with further experiments, but first wish to communicate that from our perspective the controls for these elements were already a strength of the original submission.

To control for the effects of both experimental handling artefacts and exogenous protein confounds, we have included in every experiment a reverse Aβ peptide control that is injected into sibling larvae at the same time as the experimental oligomers, under the same handling and surgical stress and injected at the same concentrations to account for generalized response to proteins, and then tracked the reverse peptide injected and oligomer injected larvae side by side in the same video tracking set-up. Thus, the only difference between the controls and experiments shown in every panel is the inclusion Aβ oligomers vs. a control peptide.

Nevertheless, we have added additional experiments with anaesthesia only, mounting only and injection only controls (new Figure 1---figure supplement 1H-I). Our results demonstrate that the initial placement of fish into behavior boxes at the beginning of the video-tracking is responsible for differences between our experimental setup and other tracking experiments (e.g. Figure 1---figure supplement 1J-K) and is not due to heart-injection, anaesthesia, or mounting.

> On a related note, can the authors exclude toxicity, which could affect motion? They address this point by showing c-fos and ERK staining, but many different patterns are observed and none are compared to staining under baseline sleep:wake conditions. It is also disturbing that the c-fos expression is so widespread. The reversibility of the effect is important and the role of specific molecules is interesting, but these still do not demonstrate impact on wake or sleep regulation per se.

To exclude toxicity and to demonstrate the effect of Aβ is on bona-fide sleep and wake, we made 4 new experiments. First, we now compare the *c-fos* patterns induced by oligomers to untreated larvae across the sleep:wake cycle and show that the *c-fos* expression pattern of baseline sleep-wake states match the Aβ induced sleep-wake states closely (Figure 2A-C). Second, we show that Aβ engage *galanin* positive neurons, a known key sleep regulator in fish and humans (Reichert et al., 2019) in a manner consistent with inducing normal sleep and wake states (Figure 2F). Third, we show the bout structures of injected fish are indistinguishable from WT fish and are clearly distinct from seizures (Figure 1---figure supplement 3D-E and Figure 1---video 1). Finally, we show that injected fish respond to acute stimuli the same way as their WT siblings, showing they have rapid state reversibility (Figure 1---figure supplement 3C). All of the new 4 experiments support our interpretation that Aβ-induced behavioral states are bona fide sleep/wake states.

> Given that AD brains likely have oligomers of all sizes, it would be good to know what happens when short and long oligomers are infused together.

We have now added this experiment to Figure 6F. Because short and long oligomers are additive, we conclude that not only do they act on different receptor molecules but also likely act on separate signalling pathways/neurons (e.g. instead of in series with each other) to affect sleep. We have added some discussion about this point.

> Reviewer 1:
>
> \[...\] I have one significant concern relating to claims that these studies reveal novel functions for the endogenous Aβ. A key missing experiment in this regard is manipulation of the endogenous Aβ gene/protein (or even assessment of endogenous Ab) and thus it is unclear if exogenous (intracardiac) injection of Aβ faithfully reproduces how an endogenous neuronal pathway would deliver Aβ in terms of location, local concentrations and kinetics.

We agree that endogenous manipulation of Aβ levels would be ideal, but we know of no experimental methodology that would allow for the acute manipulation of *only* endogenous Aβ that can also control for oligomer type. For example, genetic manipulation of APP, either through mutation or overexpression of multiple, mutated copies as is done in mouse AD research, will also affect the formation of other APP cleavage products, many of which are known to regulate biological processes, and these effects will accumulate over time, with little to no temporal control over the process. This consideration dictated our methodological choice from the start, and we built in several controls to ensure that the delivery of Aβ would be at very low concentrations and not would damage the brain (heart injections).

However, the reviewer raises a critical point about the characterization of endogenous Aβ in zebrafish. To address the point experimentally, we tested three different antibodies to detect endogenous levels of Aβ in zebrafish. We were able to detect very faint bands with the commonly used 4G8 -Aβ antibody (4G8 maps to residues 18--23, conserved between zebrafish Appa and human amyloid beta). However, the sensitivity was not enough to reliably detect endogenous Aβ in either larval or adult zebrafish ([Author response image 1](#sa2fig1){ref-type="fig"}). We then ordered a high sensitivity immunoassay kit (V-PLEX Plus Aβ42 Peptide (4G8), which has a dynamic range of 0.516-1271 pg/mL. However, we did not receive it and could not continue our experiments due to the Covid-19 outbreak.

This outcome is consistent with the zebrafish literature. There are many papers using zebrafish for AD research; however, there are no reports of detection of endogenous amyloid beta in larval zebrafish. One paper claims to measure endogenous Aβ levels in larval zebrafish using Westerns (Nery et al., 2017), but bands under 20 kDa are not labelled with a protein ladder making it unclear whether these really correspond to the Aβ band at 4 kDa (or dimers and trimers at \~8 and \~12 kDa or some other species). Wilson and Lardelli developed an assay to measure y-secretase activity in zebrafish but used an artificially modified form of App instead of the endogenous zebrafish App (Wilson and Lardelli, 2013). One study of brain-wide proteomic changes in *bace-1* mutant vs. wild type zebrafish found that zebrafish Appa and Appb proteins accumulate to higher levels in the *bace-1* mutants, suggesting that App processing in the zebrafish is conserved (Hogl et al., 2013). Thus, we believe that detection of zebrafish Aβ is not due to a difference of App processing between species but rather due to the lack of sensitivity of the antibodies.

Although a precise quantification of Aβ in the zebrafish brain remains elusive, the Hogl et al., 2013, proteomics analysis does allow for an estimate of zebrafish Appa and Appb protein levels, as well as the amount they are processed by Bace-1. Benchmarking their reported intensity‐Based Absolute Quantification (iBAQ), which scales proportionally to Molar concentration, for Appa and Appb against one of the most abundant fish brain proteins, Ependymin (estimated at 16 mM in fish ECF), allows for a rough estimate of protein concentration. We estimate from this that Appa is present at 1.7µM and Appb at 3.2µM. Since *bace-1* mutants accumulate 2-fold more Appa and 3-fold more Appb, this suggests that 50-66% of all zebrafish App is processed by *bace-1*. Thus, our estimate of 30-300 pM for the oligomer injections is 4-5 orders of magnitude lower than the concentrations of App, consistent with our other estimates. We recognize that this is only an indirect estimate and does not replace the need for measuring endogenous levels of Aβ and its oligomers at various sites in the zebrafish brain. We do believe it reinforces our contention that the concentrations we have injected are very low and reasonable, especially when compared to other typical in vivo and in vitro studies.

> I think the findings are significant and important on their own without having to make this claim which in this case is highly speculative. I would suggest either addressing experimentally or rewording and de-emphasizing this point in the text to make clear the speculative possibilities. In any case, these shortcomings should be more forthrightly noted.

We agree that our findings are important without having to make a strong claim about endogenous processes. We have therefore followed the advice of reviewer 1 and modified our text to tone down the claim that injection of Aβ would reveal endogenous functions of Aβ. Specifically, we changed the following in the text:

The Summary now reads: "Our data indicate that Aβ can trigger a bi-directional sleep/wake switch"

The Introduction now reads: "the various biological effects of Aβ -- in health or disease -- remain obscure."

The Introduction now reads: "Aβ may directly modulate sleep-regulatory pathways"

The Introduction now reads: "Isolating the specific biological effects of Aβ has been experimentally difficult."

The Discussion now reads: "Although the exogenous application of Aβ oligomers in our experiments limit the conclusions we can draw about endogenous functions of Aβ, which in vivo may present with different structure, local concentrations, and kinetics, our bi-directional Aβ modulation of sleep and wakefulness (Figure 6G) predicts that alterations to the relative concentrations of different Aβ oligomeric forms during healthy aging and AD disease progression may have opposing consequences on sleep and wake behavior."

Finally, we have added the following sentence to the Discussion: "Our model investigates alterations in sleep/wake behavior due to acute changes in exogenously delivered Aβ levels. Thus, it is possible that the sleep/wake effects observed in our study may be different than those observed when Aβ fluctuates over 24hr or when it is chronically accumulating as in AD."

> Reviewer 2:
>
> The use of zebrafish to investigate the role of beta amyloid polymers on sleep/wake regulation is potentially interesting as AD patients suffer from insomnia. Here Ozcan and colleagues inject oligomers synthesized in vitro into the fish neonate hearts and fish motion was then recorded and used as a proxy for sleep and wake states. The authors found a correlation between the polymer length and the impact on fish motor and brain activity.

We thank the reviewer for finding our work potentially interesting. For clarity, we would like to highlight some points about measuring sleep and wake states in zebrafish. While fish motion is indeed recorded as a proxy for sleep and wake states, it is well established that inactive bouts in larval fish lasting longer than 1 minute have all of the behavioral criteria for being bona fide sleep, including circadian and homeostatic regulation, characteristic sleep postures, and changes in arousal thresholds in response to stimuli across multiple modalities (Barlow and Rihel, 2017; Prober et al., 2006; Rihel et al., 2010; Zhdanova et al., 2001). Importantly, these bouts are regulated by pharmacology, genes, and neural circuits that are conserved from human to fish (Berridge et al., 2012; Carter et al., 2012; Prober et al., 2006; Zhdanova et al., 2001). We would also like to stress that waking activity (during active bouts, how active is a larva---e.g. taking a stroll or running sprints) is experimentally separable from sleep duration (e.g. see (Rihel et al., 2010).

> While the findings are potentially interesting, several points are unclear if concerning to the reviewer:
>
> 1\) First, all the experiments and interpretations rely on overexpression of Aβ polymers, there is no description or investigation in this study of the normal baseline of Aβ accumulation in this species. One would expect to see such data in Figure 1 and Figure 1---figure supplement 1 for example. Is there in fish a night vs. day, sleep vs. night rhythm of Aβ accumulation/expression?

Please see the response to reviewer 1 about the challenges we faced to quantify the level of Aβ in zebrafish. However, even if we were successful in detecting Aβ, it would have been extremely difficult to detect a sleep/wake rhythm of Aβ in zebrafish. To our knowledge, a daily rhythm of Aβ has only been detected in measurement of the ISF/CSF (Holth et al., 2019; Kang et al., 2009; Roh et al., 2012), but this rhythm is not detected in whole tissue homogenates in mammals (e.g.(Kang et al., 2009)). Since the total CSF in one zebrafish larval brain is only \~6.5 nl (Fame et al., 2016), and typical experiments can only remove 1-2 nl of fluid per animal, it was not feasible to extract CSF from 900-5000 larvae to obtain \~5 μl of CSF for a single timepoint analysis, let alone the numbers that would be needed across 24hr.

> 2\) The fish undergo anesthesia and heart perforation and are recorded a few hours later. How do handling, surgical stress, and confounds of prior anesthesia can be eliminated from \"sleep-wake\" data interpretation?

To control for the effects of both experimental handling artefacts and exogenous protein confounds, we have included in every experiment a reverse Aβ peptide control that was treated prior to injection the same as the Aβ oligomers, then injected into sibling larvae at the same time as the experimental oligomers, under the same handling and surgical stress, and tracked the reverse peptide injected and oligomer injected larvae side by side in the same boxes. To be clear, in every figure, we display a matching set of reverse peptide controls for comparison. Thus, while we cannot rule out synergistic effects between the Aβ oligomers and stress/anesthesia, the effects we describe must be due to the Aβ oligomer type, because this is the only variable that is different from the controls.

Nevertheless, we wanted to know how our handling was affecting the initial behavior. In the original manuscript (Figure 1---figure supplement 1J), we demonstrated that there is a handling effect that lasts for several hours after injection, as seen by comparing PBS injected larvae to larvae placed in the boxes on a prior day. However, we found that our experimental results are unchanged if we omit or include these first 5 hours in our analysis (Figure 1---figure supplement 1K).

To further dissect the effects of anaesthesia, mounting/unmounting, and injecting into the heart, we have added additional experiments (anaesthesia only; mounting only; injection only) to the figure (Figure 1---figure supplement 1H-I). Since each of these produce a similar subsequent behavioral effect that is statistically indistinguishable from each other, we conclude the effects on behavior is due to initial placement of larvae into tracking systems at the beginning of the video-tracking and not the heart-injection, anaesthesia, or mounting.

> 3\) It is hard for the reader to distinguish a specific effect on sleep/wake. Increased or decreased motion could be due to toxicity or specific stimulation of neuronal circuits due to non-physiological presence of exogenous oligomers. The authors try to tackle this issue with c-fos and ERK staining, but Figure 2 shows at least 6 different staining patterns, none of them compared to a sleep/wake baseline of staining. It is quite worrisome to see such a broad over expression of c-fos throughout the brain when Aβ is accumulated. Are the fish having a seizure?
>
> Toxicity could lead to reduced motion and even if it\'s reversible it can still be transient toxicity until oligomers are washed out. Hyperactivity could be due to aspecific overstimulation of neurons as illustrated by c-fos and ERK staining.

We thank the reviewer for raising important points. We now show by 4 new experiments that sleep/wake states induced by Aβ are indeed specific, acutely reversible (e.g. not paralysis/coma) and engage endogenous sleep-wake active neurons and peptides.

A\) The reviewer points out that the *c-fos* patterns induced by various Aβ oligomers were not compared to baseline staining during sleep/wake states, making their interpretation more difficult. We now provide *c-fos* staining for larvae just after light ON (ZT1, or 10am, when they are maximally awake), ZT13, when they are awake an hour before lights OFF, and in the middle of the night (ZT 19, or 4am), when larvae are mostly asleep. This data demonstrates that the Aβ^short^ injected fish brain activity pattern is highly similar to the day (baseline awake) samples collected at ZT1 (Figure 2A, C). Although *c-fos* is upregulated in many regions, including the posterior hypothalamus and the dorsal and ventral telencephalon, these areas are also upregulated in the awake larvae at ZT1. We now point to 9 discrete populations that are *c-fos* positive in both sets. This is different to the massive, non-specific upregulation of *c-fos* seen in seizures (Baraban et al., 2005; Reichert et al., 2019). Similarly, *c-fos* expression following Aβ^long^ injections, which was globally dampened relative to Aβ^rev^, is consistently low, similar to the low level of *c-fos* observed in ZT19 sleeping brains.

B\) The reviewer asks whether Aβ injected fish have seizures. Seizures in zebrafish can be induced with the epileptogenic drug, PTZ, and are readily detected in larval zebrafish from behavioral analysis (Baraban et al., 2005). WT fish display characteristic "burst-and-glide" swimming movements that are characterized by a short single forward or turning movement followed by a short pause. This bout structure is not detected in animals having seizures, which have uncoordinated bout structures. We now provide tracking data and representative videos for Aβ^rev^, Aβ^short^ and Aβ^long^ injected fish, which all have similar bout structures to uninjected wild type larvae (Figure 1---figure supplement 3D, and Figure 1---video 1). They do not display bouts that resemble seizures (compare to the PTZ treated larvae in Figure 1---figure supplement 3D). Following the analysis of Reichert et al., 2019, we quantified seizure behavior as the presence of high frequency bouts (HFB), which are present in 10 mM PTZ exposed larvae but not untreated larvae, and found that HFBs are not detected in Aβ injected fish, as in uninjected controls (Figure 1---figure supplement 3E).

C\) The reviewer suggests that reduced motion seen after injecting Aβ long could reflect toxicity. To test this, we asked whether the inactive states of these larvae were acutely reversible to the same degree as wild type larvae. Larvae in natural sleep states can be aroused into wakefulness by strong salient stimuli, such as a sudden switch in lighting (Prober et al., 2006). Conversely, animals that are paralyzed, in a coma, or displaying sickness behavior (e.g. various toxic effects) do not easily reverse into waking states. We tested this by using 10 min-dark pulses which induces a characteristic response in WT larvae\-- rapidly heightened activity when the lights turn off and reversal to baseline activity when the lights turn on. We observe that Aβ^short^ and Aβ^long^ injected fish show a response indistinguishable from WT siblings (Figure 1---figure supplement 3C), indicating that they have not lost their ability to respond to salient stimuli as might be expected from a state of generalized toxicity.

D\) If the behavioral states induced by Aβ are indeed real sleep/wake states, oligomers should engage known sleep/wake regulatory pathways. Galanin-expressing neurons are active and *galanin* expression is increased during sleep in larval zebrafish (Reichert et al., 2019). Thus, we tested whether Aβ injections alter the number of strongly *galanin* expressing neurons in the hypothalamus, which correlates with sleep state (Reichert et al., 2019). We did in situ hybridization (ISH) for *galanin* 4-6 hours post-injection. All staining steps for different groups was done in the same tube to eliminate variations in ISH procedure, and subsequent neuron counts were done blindly. Consistent with Aβ^long^ inducing sleep and Aβ^short^ inducing wakefulness, we observed a slight decrease (-6%) in hypothalamic *galanin* cell number in Aβ^short^ injected fish and a slight increase (+12%) in Aβ^long^ injected animals compared to Aβ^rev^ injected fish (Figure 2F-G). From blinded counts, *galanin* cell numbers between Aβ^short^ and Aβ^long^ injected fish were significantly different from each other (p\<0.01, Kruskal-Wallis). We have included represented images and analysis of these *galanin* changes in Figure 2F-G.

> 4\) Injections in mutant backgrounds indeed show some specificity in binding/interaction but still it does not demonstrate that the impact is on wake or sleep regulation per se. Again only motion or broad brain staining (at one time point...) are shown. An alternative interpretation is that adrb2a, pgrmc, prp1 can indeed bind Aβ but relay the toxic or aspecific impact of oligomers over expression in a brain that normally does not accumulate such molecules.

Please see our points addressing comment 3 that detail our attempts to demonstrate the impact on sleep/wake regulation per se, especially the induction of wild type sleep/wake *c-fos* patterns and effects on sleep circuits like *galanin.* The *c-fos* patterns induced by oligomers is similar to changes in WT *c-fos* patterns over 24 hours, which is consistent with an interpretation that oligomers induce normal brain state changes. Additionally, Aβ^long^ engages known sleep-regulatory pathways such as *galanin*, and *galanin* expression is reduced in Aβ^short^ injected animals, which is also consistent with these changes being sleep/wake states. Together, these observations suggest that the induced states are not general toxicity but rather acute signalling events.

However, we take the point that it is difficult to completely rule out "toxicity" -- for example even engagement of sleep circuits could be due to these circuits being the site of "toxic" effects. Even so, given the changes in Aβ composition in Alzheimer's Disease patients, the demonstration of acute effects on sleep-regulating circuits should still be of wide interest.

We have added some more caveats to our interpretation to the Discussion section. Specifically, we added: "Although the exogenous application of Aβ oligomers in our experiments limit the conclusions we can draw about endogenous functions of Aβ, which in vivo may present with different structure, local concentrations, and kinetics, our bi-directional Aβ modulation of sleep and wakefulness (Figure 6G) predicts that alterations to the relative concentrations of different Aβ oligomeric forms during healthy aging and AD disease progression may have opposing consequences on sleep and wake behavior." and "Our model investigates alterations in sleep/wake behavior due to acute changes in exogenously delivered Aβ levels. Thus, it is possible that the sleep/wake effects observed in our study may be different than those observed when Aβ fluctuates over 24hr or when it is chronically present as in AD".

> This study has the potential to be extremely interesting but many controls and demonstration of endogenous Aβ role on sleep-wake cycle are needed.
>
> Reviewer 3:
>
> \[...\] 1) While the experiments are well performed and the data intrinsically consistent, the applicability to mammals (and humans) is a consideration. Infusion of Aβ into the heart of larvae is a highly artificial system, and events that occur during sudden changes in Aβ levels may be different that those observed when Aβ is chronically present (as in AD). For example, infusion of Aβ peptide into the brain of mice or rats can induce acute, local neurodegeneration that is not observed in APP transgenic mice with chronically elevated Aβ levels. This is a fundamental shortcoming of the model, and there is little that can be done to address it, but it should be perhaps mentioned in the Discussion.

We would like to point out that we cannot detect any increase in neurodegeneration in our study (Figure 1---figure supplement 2), unlike the examples mentioned from injections in the brain of mice and rats. However, we agree our method has shortcomings relative to endogenous manipulations. We have made many changes to the text to make this shortcoming clearer. Please see responses to reviewer 1 and 2 for detailed examples of these changes.

> 2\) The implications of this bidirectional effect of short and long oligomers for sleep phenotypes in AD are also a bit unclear, as oligomers of all sizes are likely present in AD brain (though perhaps in different ratios as the disease progresses). It would be helpful to determine which pathway is dominant when both short and long oligomers are infused together, perhaps in different ratios. This is the only experiment I would request.

Thank you for the suggestion for this experiment, which we believe also provides insight into whether the Aβ^short^ and Aβ^long^ are signalling onto the same or distinct neuronal circuit pathways or signalling cascades. To address which molecular pathway dominates if both short and long oligomers are present, we injected Aβ^rev^, Aβ^short^ and Aβ^long^ alone or the short and long oligomers mixed in a one to one ratio (Aβ^mix^). Confirming our previous results, the short and long oligomers gave opposite sleep phenotypes (p\<0.01, Kruskall-Wallis) in 4 new independent experiments. The sleep-wake phenotype of the Aβ^mix^ lies between the Aβ^short^ and Aβ^long^ injected animals (Figure 6F), consistent with an additive effect of the two oligomers. This suggests that the long and short oligomers affect independent neuronal pathways/signalling cascades in addition to acting through distinct receptors (Adrb2a/Pgrmc1 vs. Prp). Future experiments will be needed to map the specific circuits involved, for example by testing whether systematic replacement of the receptors into subsets of neuronal circuits on mutant backgrounds can rescue the effects of Aβ oligomers.

We have added the following lines to describe this new data: "Co-injection of both Aβ^short^ and Aβ^long^ resulted in an intermediate phenotype that is indistinguishable from control injections of Aβ^rev^ (Figure 6F), suggesting that the effects of Aβ^short^ and Aβ^long^ are additive and likely act through distinct neuronal circuits or signalling cascades to modulate sleep. Considering this result together with the genetic and pharmacological data, we propose a bi-directional model of Aβ sleep regulation in which Aβ^short^ and Aβ^long^ act through distinct receptors and neuronal pathways to independently modulate behavioral state (Figure 6G)."
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